Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial

DSpace Repository

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial

Author: Dimopoulos, Meletios A.; Lonial, Sagar; Betts, Keith A.; Chen, Clara; Zichlin, Miriam L.; Brun, Alexander; Signorovitch, James E.; Makenbaeva, Dinara; Mekan, Sabeen; Sy, Oumar; Weisel, Katja; Richardson, Paul G.
Tübinger Autor(en):
Weisel, Katja
Published in: Cancer (2018), Bd. 124, H. 20, S. 4032-4043
Verlagsangabe: Wiley
Language: English
Full text: http://dx.doi.org/10.1002/cncr.31680
ISSN: 1097-0142
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)